Southern Shrimp Alliance Criticizes FDA for Lack of Response to Antibiotics in Indonesian Shrimp
The Southern Shrimp Alliance has criticized the FDA for failing to address an "unprecedented amount" of banned antibiotics in imported Indonesian shrimp, according to an Oct. 7 statement by the group.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
The alliance said that the FDA has "already refused more entry lines of Indonesian shrimp" due to the presence of banned antibiotics in 2025 "than in any previous year." The FDA has formally refused 13 entry lines of Indonesian shrimp in 2025 compared with its refusal of only two entry lines between 2019 and 2024, the alliance said. "Nevertheless," it said, "the FDA has not taken any additional action to respond to the risk to human health created by what appears to be a significant change in Indonesian shrimp aquaculture."
While the FDA has taken action to address the presence of Cesium-137 in shrimp from Indonesia, requiring import certification for shrimp from certain regions of the country (see 2510030022), the alliance said that it is "unclear what practical impact" the certification requirement will have on imports of Indonesian shrimp to the U.S.